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The Ovarian Cancer Audit Feasibility Pilot is a collaboration between the gynaecological 
oncology clinical community, the charity sector and Public Health England to perform 
meaningful analysis of routinely collected data for the purposes of improving treatment 
and outcomes for women diagnosed with ovarian cancer in England. The Ovarian 
Cancer Audit Feasibility Pilot is jointly funded by the British Gynaecological Cancer 
Society, Target Ovarian Cancer and Ovarian Cancer Action and is being delivered by 
analysts at the National Cancer Registration and Analysis Service (NCRAS), part of 
Public Health England. The pilot will run for 2 years and will publish a range of data 
outputs on ovarian cancer throughout that time, including a final report on the audit and 
its findings, bringing all the analysis into one place. Outputs can be found on the project 
website. 
 
This document constitutes the first report of a series of analyses throughout the 2-year 
project. It provides a detailed insight into the status of this disease in England at the 
commencement of the project, including details of disease incidence, mortality and 
survival. In keeping with international ovarian cancer analyses, we have included cases 
of ovary, fallopian tube and primary peritoneal carcinomas within our definition of 
“ovarian cancer” in these analyses, and for the survival statistics we have excluded 
ovarian tumours of borderline malignant potential. We have also provided survival 
statistics with borderline tumours included for historical comparison purposes. 
 
The analyses are achieved by linking databases which capture clinical data on cancer 
and its treatment in routine day-to-day practice in NHS hospitals in England. The 
Cancer Outcomes and Services Dataset (COSD) captures details of every cancer 
diagnosed in NHS organisations, including pathology details and a set of important 
clinical parameters such as disease stage and WHO performance status. Details of 
chemotherapy treatments are captured in the Systemic Anti-Cancer Therapy (SACT) 
dataset, and extensive data relating to hospital treatments including surgical procedures 
and patient comorbidities can be derived from Hospital Episode Statistics (HES) 
datasets. The Cancer Waiting Times (CWT) data set captures details of the pathways 
leading to the diagnosis of cancers in England, and Office for National Statistics data 
enables insight into the deaths of cancer patients, either from cancer or other causes. 
 
The analysts in the NCRAS, in collaboration with representatives of the 3 funding 
charities, have identified cases of ovary, fallopian tube and primary peritoneal 
carcinomas and by linkage to these additional datasets have produced the following 
analyses to profile the disease in England. This is a new, streamlined approach to 
clinical audit. Rather than collect fresh information, it uses data already collected by 
medical teams and engages with clinicians through existing clinical networks. The 
quality and subsequent success of the project is therefore dependent on the level of 




completeness and accuracy of the data captured in these datasets, and extensive work 
is being done with the provider NHS Trusts and multidisciplinary teams (MDTs) to 
optimise the quality of data. The latest completeness information is available to 
providers via the CancerStats portal. 
 
This initial disease profile report is intended to enable comparison with international 
jurisdictions, and identification of regional variation which should lead to improvements 
in clinical practice and outcomes in due course. Data presented in this report are also 
available in the accompanying Excel workbook. 





Incidence of ovary, fallopian tube and primary peritoneal carcinomas, 2015 to 
2017 
There were 6,902 diagnoses of ovary, fallopian tube and primary peritoneal carcinomas 
per year on average in England in 2015 to 2017 (20,707 over the 3-year period), 
including tumours with borderline malignant potential. The overall crude incidence rate 
for the period was 24.7 cases per 100,000 person-years. See Appendix 1 for cohort 
definition in terms of ICD-10 and ICD-O-2 codes. 
 
Age standardisation was used to enable comparison of Clinical Commissioning Groups 
(CCGs) with different age profiles. Age standardised incidence rates in the 195 CCGs 
ranged from 14.5 to 33.9 cases per 100,000 person-years. 
 
Incidence data by CCG, Sustainability and Transformation Partnership (STP) and 




CORRECTED Figure 1. Ovary, fallopian tube and primary peritoneal carcinomas: directly 
age standardised incidence rates by CCG, 2015 to 2017 
Source: CAS AV1906 
 




Each point on the funnel plot represents a geographical area (in this case, CCG). The 
population of each CCG is presented on the horizontal axis and the (age standardised) 
incidence rate of ovary, fallopian tube and primary peritoneal carcinomas is shown on 
the vertical axis. Some random variation in rates between areas is expected, but the 
estimate of the rate of these cancers is likely to be more precise for a larger area than 
for a smaller one. This precision level is represented by the ‘funnel’ dashed lines. Points 
that lie outside of the dashed lines indicate that such variation may not be explained 
solely by randomness but may be due to real differences in incidence between areas. 
 
Age standardisation was used to enable comparison of Cancer Alliances with different 
age profiles. Age standardised incidence rates in the 19 Cancer Alliances ranged from 
21.8 to 27.5 cases per 100,000 person-years. 
 
 
Figure 2. Ovary, fallopian tube and primary peritoneal carcinomas: directly age 
standardised incidence rates by Cancer Alliance, 2015 to 2017  
 
These funnel plots show unexpected variation in incidence of ovary, fallopian tube and 
primary peritoneal carcinomas among local geographies (identified by Clinical 
Commissioning Groups) and regional geographies (identified by Cancer Alliances).  
Previously it has been thought that regional variation in incidence may reflect 
differences in the methods and conventions used for distinguishing between ovary, 
fallopian tube and primary peritoneal carcinomas at diagnosis. However the new 
Source: CAS AV1906 
 




methodology, which includes all of these diseases in the analysis, avoids this as a 
confounding factor. Age standardisation removes the impact of differences in population 
age profile on incidence rates, but variation in ethnicity and regional variation in other 
disease risk factors such as use of hormonal contraception could impact on these data. 
 
Incidence of ovary, fallopian tube and primary peritoneal carcinomas, 2001 to 
2017 
The crude incidence rate of ovary, fallopian tube and primary peritoneal carcinomas in 
England has fluctuated at around 25 cases per 100,000 women between 2001 and 
2017. The crude rate in 2001 was 25.4 cases per 100,000 women and in 2017 it was 
observed to be 24.3 cases per 100,000 women. 
 
 
Figure 3. Crude rate of ovary, fallopian tube and primary peritoneal carcinomas in 
England, 2001 to 2017 (Source: CAS AV1907 and ONS2017) 
 
There is no significant trend in ovary, fallopian tube and primary peritoneal carcinomas 










Mortality from ovarian cancer, 2015 to 2017 
There were 3,509 deaths from ovarian cancer (C56-C57 in ICD-10) per year on average in 
2015 to 2017 (10,528 over the 3-year period). The overall crude mortality rate was 12.6 deaths 
per 100,000 person-years. See Appendix 1 for cohort definition in terms of ICD-10 codes. 
 
Age standardisation was used to enable comparison of CCGs with different age profiles. Age 
standardised mortality rates in the 195 CCGs ranged from 6.2 to 21.3 per 100,000 person-
years. Two CCGs with low rates of ovarian cancer mortality have been omitted from the funnel 
plot as their counts of ovarian cancer mortality were too small to calculate age standardised 
rates.  
 
Mortality data by CCG, STP and Cancer Alliance and for all of England are available in the 
accompanying Excel workbook. 
 
 
Figure 4. Ovarian cancer: directly age standardised mortality rates by CCG, 2015 to 2017  
 
Mortality rates from cancer are driven by many factors including incidence rates (how 
many patients get cancer), stage (how advanced their disease is at the time of 
diagnosis), comorbidities (what other conditions they suffer from) and treatments 
Source: www.cancerdata.ndrs.nhs.uk/mortality 
 




received (and whether these prolong the patient’s life). Mortality rates do not specify 
how long patients survive after diagnosis or treatment. 
  






The stage of a cancer describes the size of the tumour and how far it has grown and 
spread; a larger number indicates a later stage and more extensive disease. Disease 
staging is fundamental to the management of cancer cases, and all diagnosed cases of 
ovary, fallopian tube and primary peritoneal carcinomas should be staged by the MDT 
managing the case. When the patient is too unwell at the time of diagnosis (due to very 
advanced disease or comorbidities) to undergo full investigations and / or surgery, it 
may not be possible for the MDT to record stage data. 
 
Stage presented in this report is ‘registry stage’: the stage at diagnosis of the tumour. 
Registry stage is primarily FIGO stage provided to the registry by the diagnosing trust 
via the MDT; the registry will review this stage and combine with information from 
pathology reports and clinical investigations to record the most accurate stage at 
diagnosis possible. If insufficient data to confirm a ‘registry stage’ is available to the 
registry (from all sources) the tumour is considered to have ‘Stage unknown’ or ‘Stage 
not recorded’ in this report. 
 
For more detailed information on staging, see Appendix 2. The cohort used includes all 
ovary, fallopian tube and primary peritoneal carcinomas, including borderline tumours. 
See Appendix 1 for the cohort definition in terms of ICD-10 and ICD-O-2 codes. 
 
Stage data by CCG, STP and Cancer Alliance and for all of England are available in the  
accompanying Excel workbook. 
 
Stage at diagnosis of ovary, fallopian tube and primary peritoneal carcinomas in 
England, 2015 to 2017 
 Stage 1 Stage 2 Stage 3 Stage 4 Stage Unknown 
England 27.9% 5.4% 31.8% 18.4% 16.5% 
 
Figure 5. Stage at diagnosis of ovary, fallopian tube and primary peritoneal carcinomas 
in England, 2015 to 2017 (Source: CAS AV1906) 




Variation in stage at diagnosis of ovary, fallopian tube and primary peritoneal 
carcinomas by CCG, 2015 to 2017 
The proportion of tumours diagnosed at Stage 1 ranged from 10.0% to 47.9% among 
the 195 CCGs. 
 
Figure 6. Stage at diagnosis of ovary, fallopian tube and primary peritoneal carcinomas 
by CCG, 2015 to 2017  (Source: CAS AV1906) 
 
There are substantial differences in the stage profile across different geographies. 
Regional variation in stage data should be interpreted with care. Differences may be 
driven by how the data has been recorded or by real variation in the profile of cases 
diagnosed in different regions. Potential explanations for any real variation in stage 
profiles include differences in diagnostic pathways between regions, varying patterns of 
the time taken for patients to seek to consult their GP after first experiencing symptoms, 
inequality in ease of access in primary care to consult a GP for assessment of 
symptoms, variations in referral practices amongst GPs, and regional differences in 












Variation in proportion of ovary, fallopian tube and primary peritoneal carcinomas 
with stage recorded by CCG, 2015 to 2017 
The proportion of tumours registered with registry stage recorded ranged from 100% to 
52.6% amongst the CCGs. 
Figure 7. Ovary, fallopian tube and primary peritoneal carcinomas with stage recorded 
by CCG, 2015 to 2017 (Source: CAS AV1906) 
 
A total of 17% of cases considered in this report do not have registry stage recorded; 
this varies geographically with up to 48% of cases in particular CCGs having unknown 
stage.  
 
The Ovarian Cancer Audit Feasibility Pilot reports the completeness of stage data in the 
datasets uploaded to the cancer registry by MDTs on a routine basis, with the aim of 
improving the completeness of this data where this is clinically appropriate. This 













Variation in proportion of ovary, fallopian tube and primary peritoneal carcinomas 
diagnosed at early stage vs late stage amongst tumours with stage recorded by 
CCG, 2015 to 2017. 
The proportion of tumours diagnosed at early stage (stages 1 and 2) ranged from 62.9% 
to 21.8% amongst the CCGs. The definition of “early stage” as stage 1 or 2 and “late 
stage” as stage 3 or 4 is the same as the definition in the NHS Long Term Plan which 
sets an ambition for 75% of cancers to be diagnosed at stage 1 or 2 by 2028. 
  
 
Figure 8. Ovary, fallopian tube and primary peritoneal carcinomas diagnosed at early or 
late stage by CCG, 2015 to 2017 (Source: CAS AV1906) 
 
There are substantial differences in the early stage profile across different geographies. 
Potential explanations for this variation include differences in stage completeness, as 
well as referral and diagnostic pathways. This project’s future work analysing Routes to 
Diagnosis and treatments for ovarian cancer in England may help to disentangle the 
causes and consequences of variation in stage at diagnosis.    





Net survival rates for 2013 to 2017 diagnoses of ovary, fallopian tube and primary 
peritoneal carcinomas excluding borderline tumours 
The following are net survival rates for 2013 to 2017 diagnoses in England of ovary, 
fallopian tube and primary peritoneal carcinomas (C56-C57, C48 excluding sarcomas), 
excluding all borderline tumours and excluding all tumours coded to D39.1 in ICD-10. 
See Appendix 1 for cohort definition in terms of ICD-10 and ICD-O-2 codes. All rates 
are net rates, age standardised with International Cancer Survival Standard (ICSS) 
weights. Net survival rates compare the survival of cancer patients with that of the 
general population. See Appendix 3 for more information on survival methodology. 
 
Survival data by STP, Cancer Alliance, NHS Region and for all of England are available 
in the accompanying Excel workbook. 
 
Net survival rates of patients with ovary, fallopian tube and primary peritoneal 
carcinomas excluding borderlines at one and 5 years, 2013 to 2017 diagnoses 
For ovary, fallopian tube and primary peritoneal carcinomas, excluding borderlines in all 
of England, the one-year net survival rate was 68.0%, and the 5-year net survival rate 
was 34.6%. 
 
Figure 9. Net survival rates of patients with ovary, fallopian tube and primary peritoneal 
carcinomas excluding borderlines at one and 5 years, England, 2013 to 2017 diagnoses 
(Source: CAS AV2017) 




Net survival rates of patients with ovary, fallopian tube and primary peritoneal 
carcinomas excluding borderlines at one and 5 years by Cancer Alliance, 2013 to 
2017 diagnoses 
One-year net survival for the 19 Cancer Alliances varied between 62.9% and 75.2%, 5-
year net survival varied between 28.6% and 49.6%. 
 
 
Figure 10. Net survival rates of patients with ovary, fallopian tube and primary peritoneal 
carcinomas excluding borderlines at one and 5 years by Cancer Alliance, 2013 to 2017 
diagnoses (Source: CAS AV2017) 
 
Variation in survival between regions may suggest possible variation in the quality of 
treatment (surgery and chemotherapy) between different gynaecological cancer 
centres. However, survival is also dependent on many other factors, including the profile 
of the population being treated and access to care. For example, there are differences 
in age, general health (including comorbidities), ethnicity and socioeconomic profiles of 
different regional populations across England, which could all impact on survival 
following a diagnosis of ovarian cancer. Additionally, there may be variation in the 
provision of primary care which would restrict access for patients in some areas to 
primary care services.   
 
One-year survival is often considered to be an indicator of late presentation of 
malignancy, with poor one-year survival associated with diagnosis at late stage. In 
ovarian cancer, the patient’s ability to undergo treatment once diagnosed (measured by 




their WHO performance status score) is an important indicator of late diagnosis. If data 
completeness allows, performance status will be used in the planned output on short-
term mortality. Five-year survival is more likely to reflect the quality of treatment 
administered by the gynaecological cancer MDTs, in addition to the other associated 
factors mentioned above.  
 
One of the principal aims of the Ovarian Cancer Audit Feasibility Pilot is to explore 
these complex factors in order to understand variations in treatment approaches 
between Cancer Alliances. We will explore whether the survival variation seen in these 
charts can be fully explained by population factors, or whether there are examples of 
best practice in ovarian cancer management in some areas of the country which could 
be extended to other regions in order to improve outcomes for patients. 
 
Net survival rates of patients with ovary, fallopian tube and primary peritoneal 
carcinomas including and excluding borderlines at one and 5 years, 2001 to 2017 
diagnoses 
One-year net survival for ovary, fallopian tube and primary peritoneal carcinomas 
excluding borderline tumours has increased from 57.5% for 2001 to 2005 diagnoses to 
68.0% for 2013 to 2017 diagnoses. Five-year net survival estimates have also 
improved, from 25.7% for patients diagnosed in 2001 to 2005 up to 34.7% for patients 
diagnosed in 2013 to 2017. 
 
Figure 11. Net survival rates of patients with ovary, fallopian tube and primary peritoneal 
carcinomas including and excluding borderlines at one and 5 years, 2001 to 2017 
diagnoses (Source: CAS AV2017) 




The steady improvement in both one and 5-year survival rates for ovary, fallopian tube 
and primary peritoneal carcinomas likely represents improvements in various aspects of 
care in England since the turn of the century. Between 2000 and 2005 specialist 
gynaecological oncology centres with specialist MDTs were established throughout the 
country, providing access to centralised specialist surgery for all women regardless of 
where they live.   
 
The major barrier to one-year survival remains access to timely diagnosis. Data from 
the Get Data Out programme indicates that patients diagnosed at stage 4 have lower 
survival rates and lower treatment rates than those diagnosed with earlier stage 
disease. This suggests that a proportion of women may be presenting too unwell from 
advanced disease to enable the specialist teams to administer effective chemotherapy 
or surgery. The improvement in one-year survival suggests that we may be starting to 
impact on this issue, likely due to increased awareness of symptoms amongst women 
and primary care practitioners, and improved diagnostic and early treatment pathways 
in secondary care. This project’s future publications analysing Routes to Diagnosis and 
treatments for ovarian cancer in England will explore the impact of late diagnosis of very 
advanced disease on outcomes for patients. 
 
The improvement in 5-year survival likely reflects not only improving access to 
treatment, but also improving effectiveness of ovary, fallopian tube and primary 
peritoneal carcinomas treatments. There are likely to have been real improvements in 
the quality of surgery available to women diagnosed with these diseases following the 
publication of the National Cancer Plan in 2000, with the establishment of specialist 
gynaecological cancer centres throughout England. Ovarian cancer surgery is now 
performed throughout the country by subspecialist accredited gynaecological oncology 
surgeons with specialist cancer surgery training. Surgical radicality for ovarian 
malignancies has generally increased during the past 2decades, and there have been a 
number of improvements in chemotherapy treatments for newly diagnosed and 
recurrent disease. Over recent years women have had access to new maintenance 
treatments which help to prevent disease recurrence. The precise contributions of each 
of these factors are unknown, but they have all likely had an impact in the improvement 
of 5-year survival and are likely to continue to do so in coming years.  
  





This disease profile reviews all of the latest data (up to 2017 diagnoses) on incidence, 
mortality, stage at diagnosis and survival of patients with ovary, fallopian tube and 
primary peritoneal carcinomas in England.  
 
Main findings: 
• The incidence rate of ovary, fallopian tube and primary peritoneal carcinomas in 
England has remained reasonably stable since 2001. 
• Incidence and mortality rates vary among CCGs and Cancer Alliances, with variation 
beyond what might be expected by random chance, suggesting that there may be 
genuine differences between areas. 
• The proportions of patients diagnosed at early and late stages vary considerably 
around the country; some of this variability is likely due to data completeness but 
other factors should also be considered. 
• Completeness of stage data varies by geography; there is some room for 
improvement which would lead to better data quality for reporting. 
• Survival of patients with ovary, fallopian tube and primary peritoneal carcinomas has 
been improving since 2001. Improving one-year survival may reflect progress in 
diagnosing the disease sooner, with increased awareness of the symptoms amongst 
women and primary care practitioners, and improved diagnostic pathways, enabling 
more women to be diagnosed while still well enough to undergo 
treatment. Increased 5-year survival may reflect improvements in surgical and 
chemotherapy treatments. Assessment of geographic variation in survival rates may 
help to identify areas of best practice and improve the outlook for all patients.  
 
By using NCRAS data to analyse the full cohort of ovary, fallopian tube and primary 
peritoneal carcinomas and including or excluding borderline tumours as appropriate, we 
have been able to make clear comparisons between geographies and over time. 
 
Building on this new understanding, the ovarian cancer audit feasibility pilot will work to 
gain further insight into the factors behind the observed geographic variation and into 
best practices in the diagnosis and treatment of ovary, fallopian tube and primary 
peritoneal carcinomas, aiming for improved outcomes for patients. 
 
Reporting on data completeness back to clinical staff in the NHS via the CancerStats 
website is an ongoing part of the ovarian cancer audit feasibility pilot work. Improving 
the quality of data available to NCRAS about patient performance status, stage, residual 
disease and surgeon grade will enable further valuable analysis to be undertaken. 
 
Proposed further work for the ovarian cancer audit feasibility pilot includes study of 
variation in Routes to Diagnosis, treatment pathways, surgery and short-term mortality 




for patients with ovary, fallopian tube and primary peritoneal carcinomas with respect to 
geographies, age and other factors. 
  





Appendix 1: Cohort definitions  
Ovary, fallopian tube and primary peritoneal carcinomas (incidence and stage) 
The cohort of ovary, fallopian tube and primary peritoneal carcinomas used for this 
Ovarian Cancer Audit Feasibility Pilot is all tumours coded in ICD-10 and ICD-O-2 to 
 
C56 (Malignant neoplasm of ovary), 
C57 (Malignant neoplasm of other and unspecified female genital organs), 
C48 (Malignant neoplasm of retroperitoneum and peritoneum), excluding sarcomas: 
8693, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8963, 8990, 8991, 9040, 9041, 9042, 
9043, 9044, 8810, 8811 – 8921, 9120 – 9373, 9490, 9500, 9530 – 9582, 
D39.1 (Neoplasm of uncertain or unknown behaviour of ovary). 
 
Only female patients are included in the cohort. 
 
This definition aligns with international ovarian cancer analyses and is designed to 
capture all ovarian cancers; although there may be variation in the coding of the 
originating site within this group, in practice their prognosis and treatment are similar. 
The inclusion of D39.1 means that the cohort includes all ‘borderline malignant’ ovarian 
cancer. 
 
Ovary, fallopian tube and primary peritoneal carcinomas (excluding borderlines) 
(survival) 
 
Borderline malignant (“borderline”) ovarian tumours make up approximately 16% of the 
overall cohort of ovary, fallopian tube and primary peritoneal carcinomas. These 
tumours have historically been recorded as ovarian cancers, though their malignant 
potential is now understood to be lower than the rest of the group. 
 
Tumours with ICD-10 site code C56, C57 or C48 are defined as ‘borderline’ if their 
morphology code in ICD-O-2 is 8442, 8444, 8451, 8463, 8473, 8472 or 8462.  
Tumours with ICD-10 site code D39.1 are defined as ‘borderline’ if their morphology 
code in ICD-O-2 is 8144, 8260, 8313, 8380, 8381, 8440, 8441, 8460, 8470, 8480, 8481, 
9000, 9013, 9014 or 9015. However, all tumours at ICD-10 site code D39.1 are 
excluded from survival analysis in line with National Statistics methodology. 
 
In this report, survival analysis is presented for cohorts including and excluding 
borderline tumours. Their exclusion is in line with international ovarian cancer analyses 




and avoids inflation of the survival estimates due to the better survival of the borderline 
group. Hence, it gives a clearer picture of the survival of women with non-borderline 
ovarian cancer. We have provided data for the cohort both including and excluding 
borderline tumours to provide comparability to outputs that do not exclude borderlines. 
 
Ovarian cancer (mortality) 
The definition of ‘ovarian cancer’ used for mortality statistics in this report is C56-C57 in 
ICD-10. Data on mortality from ovarian cancer are derived from the ONS Mortality 
Extract which is in turn derived from causes of death recorded on death certificates, 
which do not include morphology information. Hence the more nuanced cohort 
descriptions (as used for incidence, stage and survival) which rely on tumour 
morphology information are not available for this statistic. 
 
 
Appendix 2: Stage 
Stage presented in this report is ‘registry stage’: the stage at diagnosis of the tumour. 
Registry stage is primarily provided by the diagnosing trust via the MDT; the registry will 
review this stage and read pathology reports and clinical investigations to record the 
most accurate stage at diagnosis possible. 
 
The 2 main staging systems used for ovarian cancer are FIGO and TNM. Where FIGO 
registry stage is available, this is used; otherwise TNM registry stage is used. 
 
Appendix 3: Survival methodology 
Net cancer survival rates (i.e. estimated survival rates as if cancer were the only 
possible cause of death) were calculated in a relative survival framework using a 
complete approach with follow-up to 5th January 2019. Results were age standardised 
using ICSS weights where numbers permitted. Cancer Survival SOP v11_0 was 
followed, using stns in Stata 15.1. 
 
  




Appendix 4: Glossary 
Age standardised rate, 
Directly standardised rate 
ASR, 
DSR 
Age standardised rates are used to compare rates 
for different populations accounting for differences 
in age distribution. They identify differences 
between populations which are not due to 
differences of their age distributions. 
Directly standardised rates are a specific way to 
calculate age standardised rates using a 
‘standard’ population (European Standard 
Population 2013) as a reference. Directly 
standardised rates adjust for age by assuming that 
the age distribution of the population being studied 
is the same as that of the standard population. 
This enables direct comparisons between 
populations with different age profiles. 
Directly age standardised rates are used for 
incidence, mortality and survival rates in this 
report. 
Borderline/non-Borderline   Borderline ovarian tumours are abnormal cells that 
form in the tissue covering the ovary. They are 
different to ovarian cancer because they do not 
grow into the supportive tissue of the ovary (the 
stroma). They tend to grow slowly and in a more 
controlled way than cancer cells.  
The main treatment for borderline tumours is 
surgery. Most women are cured and have no 
further problems. There is a small risk of the 
tumour coming back. Very rarely, the borderline 
tumour cells change into cancer cells. 
Cancer Alliances  CA The 19 Cancer Alliances in England bring together 
the key organisations in their regions to coordinate 
cancer care and to plan for and lead delivery of 
improved outcomes for patients locally. 
Cancer Analysis System CAS, AV The Cancer Analysis System is the database 
system maintained and used by the National 
Cancer Registration and Analysis Service, 
containing data on all tumours registered in 
England. Versions of the CAS are indicated by 
“AV” with a numerical indication of the date of the 
data. Data in this report are derived from the CAS. 
Further documentation can be found in the Data 
Resource Profile cited below. 
Cancer registry NCRAS The National Cancer Registration and Analysis 
Service (NCRAS) collects data on all cases of 
cancer that occur in people diagnosed in England. 
The data is used to support public health, 
healthcare and research. 
Carcinoma  Category of types of cancer that develop from 
epithelial cells. 






CCGs Clinical Commissioning Groups (CCGs) 
commission most of the hospital and community 
NHS services in the local areas for which they are 
responsible. Commissioning involves deciding 
what services are needed for diverse local 
populations and ensuring that they are provided. 
All GP practices now belong to a CCG, but CCGs 
also include other health professionals, such as 
nurses. 
Comorbidity  A disease or condition that someone has in 
addition to the health problem being studied or 
treated (i.e. cancer). 
Complete approach  Method of survival analysis that includes all 
patients diagnosed until the end of a maximum 
follow up time. 
Count  Number of patients or of tumours with relevant 
characteristics. 
Crude rate  Rate derived directly from the counts of relevant 
patients/tumours and the size of the population. 
For example, the crude incidence rate of ovarian, 
fallopian tube and primary peritoneal carcinomas 
in 2017 is the number of such tumours diagnosed 
divided by the number of women alive in England 
in that year. 
Because cancer is not common, this is often 
multiplied up and expressed as a count per 
100,000 person-years. 
Emergency Presentation  An emergency presentation is a diagnosis of 
cancer that arose from an unscheduled (or 
emergency or unplanned) hospital admission. This 
is to be contrasted with other Routes to Diagnosis, 
for example, diagnosis via referral from a GP. 
Fallopian tube  Fallopian tubes carry eggs from the ovaries to the 
uterus. Serous carcinomas of the fallopian tube 
are considered to be the same disease entity as 
serous cancers of the ovary and primary 
peritoneal carcinoma, which is why cancers at all 3 
sites are collected in this report. 
FIGO stage FIGO System for staging of gynaecological cancers, 
published by the International Federation of 
Gynaecology and Obstetrics (FIGO). 
ICD codes  ICD International Classification of Diseases is a 
medical classification and coding list for the 
identification of diseases, signs and symptoms, 
abnormal findings, complaints, social 
circumstances and external causes of injury or 
diseases, as maintained by the World Health 
Organization (WHO). 




ICD-10 classifies cancers by site and behaviour 
(malignancy) and ICD-O classifies cancers by site, 
morphology and behaviour. 
Incidence   The number of new cases of cancer, usually 
expressed as a rate by dividing by the 




ICSS Weights used for age standardisation of survival 
data for cancer. The weights reflect the age 
distribution for the cancer population considered, 
rather than the population at large. 
Malignant  Malignant tumours are considered to be cancer. 
Malignant means characterised by the tendency to 
become progressively worse. Often characterised 
by anaplasia, invasiveness and /or metastases. 
Morphology  Morphology is the type of a tumour, as diagnosed 
by a pathologist looking at the shape of the cells 
through a microscope. The morphological type of 
a tumour can be important in understanding how 
to treat that tumour and what expected outcomes 
might be. 
Mortality  Cancer mortality is the number of deaths from 
cancer in a specific population within a specific 
period of time, usually a year. It usually only 
includes deaths where cancer is mentioned as an 
underlying cause of death on death certificates. 
Cancer mortality is often expressed as a crude or 
age standardised rate. Cancer mortality rates are 
a standard measure of the frequency of deaths 
from cancer within a specific period of time relative 
to a fixed population size, usually 100,000 person-
years. 
Multidisciplinary team MDT MDTs bring together experts in specific areas of 
medicine and care, and usually meet every week 
to discuss the diagnosis, treatment and care of 
individual cancer patients. 
NHS Long Term Plan  The NHS Long Term Plan was published in 
January 2019 and sets out major goals for the 
NHS over the following 10 years. This includes 
some cancer-specific targets, notably a goal to 
diagnose 75% of all cancers at early stage (stages 
1 to 2) by 2028. 
NHS trusts  NHS hospital trusts are organisational units within 
the National Health Service in England, providing 
secondary health services in a particular local 
area. 
Performance status  Performance status is an attempt to quantify 
cancer patients' general well-being and activities 
of daily life. This is captured as a WHO (World 
Health Organization) score between 0 and 5. 




Peritoneum C48 The peritoneum is the serous membrane forming 
the lining of the abdominal cavity. Primary 
peritoneal carcinomas are considered to be the 
same disease entity as serous carcinomas of the 
ovarian or fallopian tube, which is why cancers at 
all 3 sites are collected in this report. 
Person-years  The size of the population in each year, summed 
over years. Using person-years for populations 
when calculating incidence and mortality rates 




 Cancer of the epithelial cells in the peritoneum. 
Primary peritoneal carcinomas are considered to 
be the same disease entity as serous carcinomas 
of the ovarian or fallopian tube, which is why 
cancers at all 3 sites are collected in this report. 
Stage   Stage describes the extent or severity of a 
person’s cancer. Diagnosis at earlier stage leads 
to improved prognosis, treatments and outcomes 
in comparison with cancers diagnosed at a later 
stage. 
Standard population ESP2013 Standard population is an example distribution of 
ages in the population and is used for direct age-
standardisation. (See “Age standardised rate” 
above.) This report uses the European Standard 
Population 2013. 
Survival  Crude survival rates are calculated as the number 
of patients who survive a certain length of time 
since their diagnosis, divided by the total number 
of patients in the group.  
Net survival rates, published here, are survival 
rates adjusted so that they better estimate the 





STP The 44 STPs are areas (covering all of England), 
where local NHS organisations and councils have 
drawn up shared proposals in their locality to 




WHO The World Health Organization directs and 
coordinates international health within the United 
Nations system. The WHO classification systems 
for cancer sites (ICD-10, ICD-O) and performance 
status are used in the cancer registry. 
  




Appendix 5: Useful links  
Ovarian Cancer Audit 
Feasibility Pilot homepage 
 
Information about this project 





NCRAS gynae hub ovarian 
cancer resources 
 
Reports, briefings and other 








NCRAS hub for incidence and 
mortality data by geographies, 
Routes to Diagnosis and treatment 











For N3 (NHS) connections 
only, requires signup. 
Incidence and mortality with 
greater geographical 




For N3 (NHS) connections 
only, requires signup. 
Select Audits > OCAFP for 




Data Resource Profile: 
National Cancer Registration 
Dataset in England 
 
Information about the registry 
dataset used for this report. 
https://doi.org/10.1093/ije/dyz076 




Get Data Out: Ovary, fallopian 
tube and primary peritoneal 
carcinomas 
 
Routine data from NCRAS on 
small groups of ovarian 
cancer patients since 2013. 
Incidence, Routes to 




Progress in cancer survival, mortality, 
and incidence in seven high-income 
countries 1995–2014 (ICBP 
SURVMARK-2): a population-based 
study, The Lancet Oncology, 
Arnold et al. 2019  
 
International comparison of cancer 
incidence, mortality and survival, 
including ovarian cancer. 
https://doi.org/10.1016/S1470-
2045(19)30456-5 
Stage breakdown by CCG 2017 
 
NCRAS stage data for sites including 
ovary, split by CCG. 
http://www.ncin.org.uk/view?rid=3864 
 
 
